Alternative glycosylation of the insulin receptor prevents oligomerization and acquisition of insulin-dependent tyrosine kinase activity  by Hwang, Joseph B. et al.
Alternative glycosylation of the insulin receptor prevents oligomerization
and acquisition of insulin-dependent tyrosine kinase activity
Joseph B. Hwang a;1, Jonathan Hernandez a, Richard Leduc b, Susan C. Frost a;*
a Department of Biochemistry and Molecular Biology, Box 100245, University of Florida, Gainesville, FL, USA
b Department of Pharmacology, Universite¤ de Sherbrooke, Sherbrooke, Que¤bec, Canada
Received 19 June 2000; received in revised form 26 September 2000; accepted 28 September 2000
Abstract
Glucose deprivation leads to the synthesis of an aberrantly glycosylated (‘alternative’) and inefficiently processed form of
the insulin proreceptor in 3T3-L1 adipocytes. To further explore the effect of aberrant (rather than absent) N-linked
glycosylation of the insulin receptor, we examined the relationship of processing to function. Our studies show that the
alternative form of the proreceptor does not oligomerize nor does it acquire the ability to undergo insulin-sensitive
autophosphorylation. This along with an interaction with the glucose-regulated stress protein GRP78/BiP implies
inappropriate folding/dimerization and retention in the ER. Glucose refeeding causes the post-translational modification of
the alternative form of the proreceptor to a novel ‘intermediate’ form which is independent of new protein synthesis. As little
as 100 WM glucose (or mannose) can induce this modification. In vitro digestion of the alternative and intermediate
proreceptors with SPC1/furin shows that both the K- and L-subunit domains are glycosylated, albeit aberrantly. This implies
that the aberrantly glycosylated proreceptor could serve as a substrate for SPC1 in a physiological setting if the receptor was
able to interact with the enzyme in the appropriate compartment (i.e., the trans-Golgi network). Based on inhibitor studies,
however, both the alternative and intermediate forms of the proreceptor appear to be primarily targeted to the proteasome
for degradation. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The mature insulin receptor (IR) is a heterotetra-
mer composed of two K-subunits (V135 kDa) and
two L-subunits (V95 kDa). However, the receptor is
initially synthesized as a single polypeptide contain-
ing the domains for both the K- and L-subunits.
Shown in Fig. 1 is a linear model of the mouse IR
sequence [1]. A hydrophobic signal sequence directs
the protein to the lumen of endoplasmic reticulum
(ER) where the ¢rst 27 amino acids at the N-termi-
nus are cleaved. The proreceptor is then co-transla-
tionally glycosylated at asparagine residues on both
the K- and L-subunits [2,3]. Oligosaccharide process-
ing begins in the ER and continues through the Golgi.
In addition to oligosaccharide processing, the prore-
ceptor undergoes dimerization and acquisition of
function in the ER [4], a process that requires approx-
imately 1.5 h. In the trans-Golgi network (TGN), the
dimeric proreceptor is proteolytically cleaved by a
member of the subtilisin-related pro-protein conver-
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tases (SPCs), possibly SPC1/furin, at a consensus se-
quence of basic amino acid residues (RKRR) en-
abling formation of the heterotetramer [5]. Move-
ment through the Golgi to the plasma membrane
requires an additional 1.5 h. At steady state, approx-
imately 95% of the IR pool exists as the hetero-
tetramer, 75% of which is at the plasma membrane
[6].
It has been known for some time that glycosyla-
tion is important for IR tra⁄cking. This was initially
demonstrated with studies utilizing tunicamycin, an
antibiotic which blocks N-linked glycosylation. This
treatment leads to the accumulation of an aglyco-
proreceptor in an intracellular compartment [7,4].
The use of castanospermine and 1-deoxynojirimcyin
(glucosidase inhibitors) also causes accumulation
rather than processing [8]. A direct correlation be-
tween glycosylation and processing has recently
been addressed using site-directed mutagenesis of in-
dividual N-linked sites. In the K-subunit, mutation of
the ¢rst four sites [9] or mutation of the ¢rst or
second pair of sites [10] leads to accumulation of
the proreceptor in the ER. Mutation of the aspara-
gines at the four N-linked sites of the L-subunit has
no e¡ect on processing, but blocks insulin-stimulated
autophosphorylation and thus signaling [11,12].
Accumulation of aberrant proteins in the ER acti-
vates the ‘unfolded protein response’, resulting in the
transcriptional upregulation of GRP78 (also called
BiP) [13]. Under normal conditions, GRP78, along
with its partners, serve as ER chaperones mediating
the correct folding and oligomerization of newly syn-
thesized proteins. Binding to proteins is thus transi-
ent. However, GRP78 is also involved in ‘quality
control’ mechanisms which prevent the exit of incor-
rectly folded proteins to the Golgi but instead se-
questers and ultimately accelerates their degradation.
In that regard, a number of mutant IRs (as synthe-
sized in overexpression systems) have been shown to
interact with GRP78 which causes their retention in
the ER [14,15].
Another class of chaperones also interact with
newly synthesized glycoproteins early in their matu-
ration. These proteins, calnexin and calreticulin, are
both calcium binding proteins which recognize
monoglucosylated glycoproteins [16]. The substrates
for these binding proteins appear to be N-linked gly-
coproteins containing a single terminal glucose gen-
erated by trimming with glucosidase I and II. Recent
studies by Bass et al. [17] show that blocking glucose
trimming of the IR in overexpressing CHO cells ac-
celerates dimerization although slows targeting to the
plasma membrane.
3T3-L1 adipocytes express a large number of cell
surface IRs, approximately 200 000 per cell [18],
making them a good model for examining IR pro-
cessing. Using this cell line, we have established a
glucose deprivation^refeeding paradigm which allows
us to examine reversible alterations in receptor pro-
cessing [6]. Our studies show that 24 h of glucose
deprivation causes the accumulation of an aberrantly
glycosylated proreceptor with little change in the ex-
pression of cell surface receptor. This ‘alternative’
form of the proreceptor does not undergo processing
but is rather degraded with a half-time of 5.1 h. This
contrasts to the exit time for normal proreceptor
Fig. 1. Linear model of the IR. The IR precursor protein is translated as a single polypeptide. Depicted are the domains containing
the K- and L-subunits and the regions which are glycosylated. The amino acid numbering derives from the mouse sequence published
by Flores-Riveros et al. [1]. This has 63% identity to the short form of the human IR.
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from the ER which is about 1.2 h. The alternative
proreceptor is retained in the ER, in part due to its
interaction with GRP78. Glucose refeeding results in
the novel post-translational glycosylation of the al-
ternative proreceptor (which we call the intermediate
form) with the sequential loss of GRP78 interaction
and accelerated movement from the ER.
The present studies serve to further the investi-
gation on the e¡ect of aberrant (rather than absent)
N-linked glycosylation of the IR. These studies show
that the alternative form does not oligomerize nor
does it autophosphorylate in an insulin-sensitive
manner. Rather the alternative proreceptor and the
intermediate form are targeted to the proteasome
for degradation. While these forms serve as in
vitro substrates for SPC1, their in vivo access to
SPC1 is limited because of compartmental segrega-
tion.
2. Materials and methods
2.1. Cell culture
3T3-L1 ¢broblasts were grown and di¡erentiated
in 100 mM plates according to the procedure of
Frost and Lane [19]. Twenty-four hours prior to
the start of a protocol, the cells were provided with
fresh DMEM containing 10% fetal bovine serum.
Cells were then fed complete medium or incubated
in glucose-free DMEM containing 10% dialyzed fetal
bovine serum for the times indicated.
2.2. Subcellular fractionation
Cells were washed with Krebs-Ringer phosphate
bu¡er (pH 7.4) and collected in TES (20 mM
Tris, 1 mM EDTA, and 255 mM sucrose, pH 7.4)
containing 1 mM phenylmethylsulfonyl £uoride
(PMSF). For total membranes, cells were homoge-
nized in a Potter Elvehjem £ask using 20 strokes of a
motor-driven Te£on pestle. Membranes were col-
lected by centrifugation at 55 K in a Ti70.1 rotor
for 70 min. For high density membranes (HDM),
cells were sheared in a steel block homogenizer and
membranes collected by di¡erential centrifugation as
described [20]. The HDM contains 88% of the ER
membranes.
2.3. Antibody production
A peptide corresponding to residues 1329^1345 of
the IR (GRVLTLPRSNPS) was synthesized by the
Protein Chemistry Core facility group at the Univer-
sity of Florida. A cysteine residue was attached to
the N-terminus of the peptide to facilitate covalent
coupling to keyhole limpet hemocyanin. The conju-
gated product was emulsi¢ed in Freund’s complete
adjuvant and injected into the popliteal lymph node
of New Zealand white rabbits [21]. The rabbit was
boosted by intradermal injection with the KLH-IR
conjugate in Freund’s incomplete adjuvant after 1
month and 2-weekly thereafter. Non-immune serum
showed no reactivity toward the peptide, while im-
mune serum detected at little as 1 ng of IR peptide.
Serum was routinely used at 1:1000 dilution in West-
ern blot analysis. For application to immunoprecipi-
tation, puri¢cation of IR-speci¢c antibodies was re-
quired which we accomplished using a peptide
a⁄nity column. Five microgram of puri¢ed antibody
was routinely used for immunoprecipitation assays.
2.4. Immunoblot analysis, metabolic labeling and
immunoprecipitation
Methodology for Western blotting using anti-IR
and anti-GRP78 serum, incorporation of [35S]meth-
ionine/cysteine and [3H]mannose into cellular pro-
teins, and immunoprecipitation of labeled IR has
been previously published [6].
2.5. Inhibitor studies
Cycloheximide prevents protein synthesis in eu-
karyotes by blocking the translocation step. In label-
ing experiments, cycloheximide was used at a ¢nal
concentration of 20 WM in DMSO. An equal volume
of DMSO was added to controls. Lactacystin, orig-
inally isolated by Omura et al. [22], is a Streptomyces
metabolite whose active form irreversibly binds to
the catalytic threonines in the active sites of the L-
subunits of the proteasome [23]. MG132 is a peptide
aldehyde which reversibly inhibits proteasome func-
tion [24]. Leupeptin inhibits cysteine proteases of
the trans-Golgi and lysosomal compartments [25].
Chloroquine and NH4Cl are both weak bases which
increase lysosomal pH inhibiting protease activity
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[26]. The protease inhibitors were added at the fol-
lowing concentrations: lactacystin (10 WM); MG132
(50 WM); leupeptin (50 WM); chloroquine (50 WM);
and NH4Cl (50 WM) in appropriate solvent. See spe-
ci¢c ¢gure legends for experimental details.
2.6. SPC1 digestion
Two procedures were followed. Isolated mem-
branes: 50 Wg of HDM membranes suspended in
TES (no PMSF) were incubated in HEPES bu¡er
(100 mM HEPES (pH 7.6), 1 mM CaCl2, and 0.5%
Triton X-100) containing 1 mM L-mercaptoethanol
(LME). Digestion was initiated with the addition of
60 units (1 Wl) of recombinant SPC1 and continued
for 2 h at 37‡C. The reaction was stopped by addi-
tion of Laemmli sample dilution bu¡er and incu-
bated at 95‡C for 5 min before applying to a 7.5%
SDS-PAGE gel. The gel was processed for immuno-
blotting. Immunoprecipitated receptor: IR was im-
munoprecipitated from total membranes (V1.4 mg)
extracted in RIPA bu¡er containing PMSF. For
wash steps, the immune complex was washed twice
with 1 ml RIPA bu¡er (no PMSF), four times with
1 ml RIPA bu¡er containing 1 M NaCl, and twice
with 1 ml HEPES bu¡er (no PMSF). Digestion
was initiated with the addition of 35 Wl HEPES con-
taining 1 mM LME and 60 U recombinant SPC1
[27]. The reaction continued for 2 h at 37‡C and
was stopped with sample dilution bu¡er. Proteins
were separated on a 7.5% SDS-PAGE gel and pro-
cessed for autoradiography.
2.7. Autophosphorylation
Proreceptor was immunoprecipitated from fed,
glucose-deprived, or deprived refed cells. The immu-
noprecipitation bu¡er was exchanged for PBS (pH
7.4) containing 1% Triton X-100 (PBS-T) followed
by two additional washes of the immune complex.
The complex was washed four times with PBS-T
containing 1 M NaCl, and twice with 1 ml HEPES
bu¡er (50 mM HEPES, pH 6.9 and 1 mM EDTA).
After aspiration of the ¢nal wash bu¡er, 30 Wl of
HEPES bu¡er plus 4 Wl of 10% Triton X-100 was
added and allowed to incubated for 30 min at room
temperature. Then 2 Wl of 100 mM MnCl2 (5 mM),
0.8 Wl of 1 mM ATP (20 WM), and 2 WCi [Q32P]ATP
was added with or without 0.4 Wl of 1034 M insulin
(1 WM) and incubated for 15 min at room temper-
ature. The reaction was quenched with 10 Wl of
5Usample dilution bu¡er. The samples were heated
to 95‡C for 5 min before loading onto a reducing
7.5% SDS-PAGE gel. The dried gel was exposed to
¢lm at room temperature.
2.8. Proreceptor oligomerization
The receptor was immunoprecipitated as described
[6] except that the receptor was released from Protein
A Sepharose beads in sample dilution bu¡er contain-
ing no LME. The sample was applied to a 3^10%
gradient gel (Jule Inc., New Haven, CT, USA) and
run overnight. The gel was enhanced with 1 M so-
dium salicylate, dried, and exposed to ¢lm.
3. Results
3.1. Altered proreceptor synthesis and interaction with
GRP78
Fig. 2 con¢rms our earlier work by showing a
representative immunoprecipitation of radiolabeled
IR from glucose-fed (F) and glucose-deprived cells
(S) using our own anti-L-subunit antibody. In fed
cells, the normal proreceptor along with the K- and
L-subunits are observed during the 3 h pulse with
[35S]methionine/cysteine. In contrast, a lower molec-
ular weight form of the proreceptor (the alternative
Fig. 2. Immunoprecipitation of IR using a⁄nity puri¢ed IRL
antibody. Glucose-fed or glucose-deprived cells were labeled
with [35S]methionine/cysteine for 3 h. IR was immunoprecipi-
tated from total membrane proteins using 10 Wg of the a⁄nity
puri¢ed IRL antibody. Immunoprecipitates were resolved by
7.5% SDS-PAGE, followed by autoradiography.
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form) predominates in the glucose-deprived cells and
neither of the mature subunits are observed. An ad-
ditional radiolabeled protein co-precipitates with the
IR in glucose-deprived cells. We have shown previ-
ously that the protein which migrates as a 72 kDa
protein is GRP782, one of the major ER chaperones
[6]. While glucose-deprivation induces the unfolded
protein response, there is little change in total protein
[28] or ATP concentration [29] and the e¡ect is re-
versible (see below) indicating that the cells have not
entered an apoptotic state.
3.2. Reversibility of aberrant proreceptor synthesis
To determine the reversibility of the glucose-dep-
rivation e¡ect, we refed cells with 25 mM glucose
after a period of 24 h of deprivation. The results
are shown in Fig. 3. This experiment di¡ers from
that in Fig. 2 in that the cells were essentially pulsed
for only 1 h which provides insu⁄cient time for the
normal receptor to process to the mature subunits.
Lanes 1 and 2 represent data from glucose-fed cells
showing the normal proreceptor. Note that cyclohex-
imide addition just prior to the pulse blocks the syn-
thesis of the receptor. Lanes 3 and 4 show data from
glucose-deprived cells to illustrate the production of
the alternative proreceptor. Once again, cyclohexi-
mide blocks the synthesis of the receptor. Lanes 5
and 6 show data from the refeeding paradigm. In
this case, cells were pulsed for 1 h in the glucose-
deprived state followed by the addition of 25 mM
glucose in the continued presence of the radiolabeled
amino acids for 1 h. The species which migrates as
the alternative proreceptor is no longer observed.
Thus the synthesis of this form ceases immediately
upon the addition of glucose. However, two labeled
proteins are observed. The upper band migrates sim-
ilarly to the normal proreceptor (compare to lane 1)
and is sensitive to cycloheximide addition. Note that
the intensities are similar because we designed the
experiment such that the level of incorporation of
labeled amino acids into the normal proreceptor
(fed cells) should equal that in the proreceptor syn-
thesized during refeeding (starvedCfed cells). The
lower band migrates at a point intermediate between
the normal proreceptor and the alternative prorecep-
tor and is insensitive to cycloheximide treatment.
This indicates that this ‘intermediate’ proreceptor de-
rives directly from the alternative proreceptor in a
post-translational process, i.e., the alternative prore-
ceptor pool is totally converted to the intermediate
form of the proreceptor. Note the co-precipitation of
Fig. 3. Processing of the alternative form of the IR. Lanes 1
and 2: cycloheximide was added or not to the medium of glu-
cose-fed cells 10 min prior to the addition of [35S]methionine/
cysteine. Cells were collected after 1 h of exposure to labeling
mix for total membrane isolation. Lane 3 and 4: cycloheximide
was added or not to the medium of glucose-deprived cells 10
min prior to the addition of label. Cells were collected after 1 h
for total membrane isolation. Lanes 5 and 6: Glucose-deprived
cells were exposed to [35S]methionine/cysteine for 1 h, the last
10 min of which included cycloheximide as indicated. Glucose
was added to the medium and cells were collected after 1 h for
total membrane isolation. Membranes were extracted for immu-
noprecipitation. The data are representative of two independent
experiments.
Fig. 4. Glucose-dependent inhibition of alternative proreceptor
synthesis. Cells were deprived of glucose for 24 h. Glucose was
added back to the medium for 3 h at the concentrations indi-
cated. Total membranes were collected and 100 Wg applied to a
reducing 7.5% SDS-PAGE gels. After transfer to nitrocellulose,
proreceptor was identi¢ed by chemiluminescence using anti-L-
subunit antibody. This dose^response represents a single experi-
ment although identical results were obtained in three independ-
ent experiments using mannose as the substrate.
2 Three criteria were used to determine the identity of the 72
kDa protein. First, the 72 kDa protein migrated identically to
immunodetected and immunoprecipitated GRP78. Second, the
pI values for the 72 kDa protein and GRP78 were identical.
Third, the alternative receptor was released from the 72 kDa
protein in an ATP-dependent manner, typical of GRP78-sub-
strate interactions.
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GRP78 with both the alternative and intermediate
proreceptors suggesting that both forms are inap-
propriately folded. Note that GRP78 is absent in
lane 4 because of the inhibition of protein synthesis,
and that the intensity of GRP78 in lane 6 is reduced
because of the addition of cycloheximide during the
second hour of labeling.
A dose^response experiment revealed that low
concentrations of glucose are su⁄cient to prevent
the synthesis of the alternative proreceptor as shown
in Fig. 4. In this experiment, cells were deprived of
glucose for 24 h followed by refeeding with speci¢c
concentrations of glucose for a period of 3 h. The
immunoblot analysis shows that with only 100 WM
glucose, the appearance of both the normal prorecep-
tor and the intermediate is observed, although there
is still some alternative form synthesized. At 1 mM,
the alternative form is clearly absent. Identical results
were observed using mannose as the sugar source
(data not shown).
Finally, we tested the incorporation of [3H]-
mannose into the proreceptor as a tag for the oligo-
saccharides. Results are shown in Fig. 5. Incorpora-
tion of [3H]mannose (420 WCi/10 WM) into the nor-
mal proreceptor is ine⁄cient. In fact, only extended
exposure of the dried gels revealed any labeling of
the normal proreceptor (compare overexposed panel
B with A). We attribute this to intracellular dilution
of the labeled mannose with glucose metabolites. In
contrast, a strong signal was observed in the alter-
native proreceptor further supporting its status as a
glycoprotein. Note that GRP78 was not detected
which con¢rms earlier ¢ndings that GRP78 is not
glycosylated [30,31]. With 1 h of chase, the inter-
mediate proreceptor is clearly labeled indicating
that the oligosaccharide initially attached to the al-
ternative proreceptor was retained. With additional
chase time, the intermediate proreceptor disappears
with a half-time of about 1 h. Two additional bands
also appear, but only with extended exposure (panel
B). We interpret this to mean that only a small frac-
tion of the intermediate proreceptor pool is pro-
cessed to the mature form of the receptor.
3.3. In vitro processing of the IR
Normal dimeric proreceptor is cleaved in the TGN
by a member of the SPC family of serine proteases,
quite likely by SPC1/furin [32^34]. However, it is
unlikely that the alternative proreceptor reaches the
TGN. To determine if the alternative (or intermedi-
ate) proreceptor can serve as a substrate for SPC1,
we developed an in vitro assay using recombinant
enzyme ([27], Denault and Leduc, in press). In Fig.
Fig. 5. Turnover of the alternative form of the IR. Cells were
maintained in medium with or without 25 mM glucose for
21 h. Cells were then provided glucose-free medium containing
[3H]mannose (420 WCi/plate) for 3 h. Glucose-deprived cells
were chased in complete medium in the absence of label for 1,
2, 4, or 6 h. At each time point, total membranes were col-
lected for immunoprecipitation with anti-L-subunit antibody.
(A) Depicts a 3 day exposure of the dried gel; (B) shows a 2.5
week exposure. This experiment was repeated twice with similar
results.
Fig. 6. In vitro cleavage of the proreceptor with SPC1. Glu-
cose-fed, glucose-deprived (48 h), or deprivedCrefed cells were
collected and the HDM fraction was isolated. Aliquots of these
membranes (50 Wg) were treated in vitro with SPC1 as de-
scribed in Section 2. Laemmli sample dilution bu¡er was added
to stop the reaction and loaded onto a reducing 7.5% SDS-
PAGE gel. After transfer, L-subunit was detected by chemilumi-
nescence. The exposure time for the proreceptor bands was
5 min, while that for the L-subunit was 1 min. Note the pres-
ence of L-subunit in glucose-fed but not glucose-deprived or de-
privedCrefed cells consistent with previous observations at 48 h
of deprivation [6]. Duplicate experiments showed identical re-
sults.
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6, cells were provided complete medium containing
25 mM glucose (F), deprived of glucose for 48 h (S),
or deprived of glucose but then refed with complete
medium for 1 h (SCF). The time of glucose depri-
vation was selected because of the complete loss of
mature receptor from the ER fraction under these
conditions3. This gives us the ability to analyze the
production of cleavage products by Western blot
analysis, which would be obscured by mature L-sub-
unit. The normal proreceptor disappears in the pres-
ence of SPC1 (upper panel, compare lane 1 and 2).
Because only 4% of the total receptor pool exists as
proreceptor in fed cells [6], its digestion does not
noticeably increase the amount of normal L-subunit
(lower panel). Note the additional band (marked
with an asterisk) whose identity is unknown but
which results from the speci¢c addition of LME in
the digest bu¡er. It is not present in glucose-deprived
samples.
Lanes 3 and 4 represent glucose-deprived cells. In
the absence of glucose, only the alternative prorecep-
tor is observed (upper panel, lane 3). Digestion with
SPC1 once again causes the complete disappearance
of the alternative proreceptor with the concurrent
production of a lower molecular weight form of the
L-subunit, which we call the alternative L-subunit
(lower panel, lane 4). In starved^refed cells, two pro-
receptor glycoforms are observed (upper panel, lane
5). The higher molecular weight species represents
newly synthesized proreceptor while the intermediate
derives from post-translational processing of the al-
ternative proreceptor. Digestion with SPC1 results in
two cleavage products: one is generated from the
newly synthesized proreceptor and appears to mi-
grate slightly faster than the proreceptor in fed cells
(de novo L-subunit). The appearance of newly syn-
thesized proreceptor can be prevented by including
cycloheximide during refeeding (see above) which in
turn prevents the appearance of the de novo L-sub-
unit cleavage product (data not shown). The other
digest product derives from the intermediate prore-
ceptor which we have called the intermediate L-sub-
unit. This form migrates more slowly than the alter-
native L-subunit which we have concluded results
from the post-translational addition of oligosaccha-
rides [6].
The experiment in Fig. 6 was essentially repeated
using [3H]mannose to label oligosaccharides. Glu-
cose-deprived cells were incubated for 3 h in the
presence of 210 WCi [3H]mannose. SPC1 digestion
once again causes the complete loss of this species
with the appearance of two predominant radiola-
beled bands (Fig. 7, compare lanes 1 and 2). The
identi¢cation of the L-subunit was con¢rmed with
anti-L-subunit antibodies (data not shown). At this
point, the identi¢cation of the K-subunit is tentative
for lack of adequate immunodetection. While the
experiment in Fig. 4 suggests that both the K- and
L-subunit domains in the alternative proreceptor are
glycosylated, Fig. 7 provides more de¢nitive proof of
this interpretation. The intermediate proreceptor
(lane 3) once again retains radioactivity initially in-
corporated into the alternative proreceptor. As with
the alternative proreceptor, the intermediate prore-
ceptor disappears in the presence of SPC1 with the
production of two major digest products (lane 4).
Fig. 7. SPC1-dependent cleavage of metabolically labeled alter-
native proreceptor. Cells were maintained in medium with or
without 25 mM glucose for 21 h. Cells were then provided glu-
cose-free medium containing [3H]mannose (210 WCi/plate) for
3 h. One set of plates was washed and chased in complete me-
dium for 1 h. Radiolabeled IR was immunoprecipitated from
total membranes. Sixty units of SPC1 were added to the im-
mune complex and incubated for 2 h at 37‡C before separation
by reducing SDS-PAGE. The ¢lm was developed after 30 days
of exposure to the dried gel. This experiment was repeated
twice with identical results.
3 The steady state level of the mature receptor as measured by
L-subunit expression does not change signi¢cantly between cells
fed for 24 h in either complete medium or glucose-free medium
[6]. While aberrant glycosylation of the proreceptor inhibits pro-
cessing, this is not observed until 15 h of deprivation. Because the
half-life of the receptor is about 14 h [18], the pool of mature
receptors is fairly constant through 24 h of deprivation.
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Thus, both the alternative and intermediate prore-
ceptors can serve as substrates for SPC1 in vitro,
but this is prevented in vivo because of the segrega-
tion between the ER compartment and the TGN.
3.4. Proteasome-dependent turnover of the alternative
and intermediate forms of the proreceptor
To determine the fate of the alternative prorecep-
tor, we examined the e¡ect of protease inhibitors
within a pulse^chase experiment (Fig. 8). Glucose-
deprived cells were metabolically labeled for 3 h
and then chased in the absence or presence of
MG132, NHCl4, leupeptin, or chloroquine for 6 h.
In the absence of inhibitors, about 50% of the alter-
native proreceptor is lost (compare lanes 1 and 2), as
anticipated given a half-life of 5.1 h [6]. While we
expected to see a block in this loss if one or more
of the inhibitors were e¡ective, we were surprised
that MG132 caused an accumulation of a lower mo-
lecular weight protein (lane 3) which could be de-
tected with anti-L-subunit antibodies (data not
shown). The other inhibitors appeared to have little
e¡ect. We explored this further by examining speci¢c
time points (Fig. 9A,B). Once again, the presence of
MG132 did not a¡ect the loss of the proreceptor but
rather favored accumulation of the L-subunit-like
product (Fig. 9A). Negligible amounts of K-sub-
unit-like product co-precipitated with the prorecep-
tor, suggesting that its covalent attachment to the L-
subunit is lost. Similar results were obtained when
lactacystin was used instead of MG132 [35]. In con-
trast to its e¡ect on the alternative proreceptor,
MG132 speci¢cally delayed the loss of the intermedi-
ate proreceptor concurrent with the accumulation of
a L-subunit-like product (Fig. 9B).
3.5. Aberrant folding of the alternative proreceptor
To determine if the alternative form of the prore-
ceptor can fold appropriately, we performed a pulse^
chase experiment to analyze immunoprecipitated re-
Fig. 9. E¡ect of MG132 on alternative proreceptor degradation.
(A) Glucose-deprived cells were prepared as in Fig. 8. During
the chase, cells were treated in the presence or absence of
MG132 for speci¢c times at which point total membranes were
collected. These were extracted for immunoprecipitation of the
IR. Immunoprecipitates were resolved by reducing 7.5% SDS-
PAGE, followed by autoradiography. This experiment was re-
peated once with similar results. (B) Glucose-deprived cells were
prepared as in Fig. 8. Glucose was added during the chase in
the presence or absence of MG132 for speci¢c times. Mem-
branes were collected and extracted for immunoprecipitation of
the IR. Immunoprecipitates were resolved by reducing 7.5%
SDS-PAGE, followed by autoradiography. This experiment was
repeated once with similar results.
Fig. 8. E¡ect of proteolytic inhibitors on alternative proreceptor
degradation. Cells were incubated in complete or glucose-free
medium for 20 h. Cells were incubated in methionine- and cys-
teine-free medium for 1 h followed by incubation for 3 h in the
presence of [35S]methionine/cysteine (400 WCi). Cells were then
chased in glucose-free medium for 6 h with or without the in-
hibitors. Total membranes were collected and IR collected by
immunoprecipitation. Immunoprecipitates were resolved by re-
ducing 7.5% SDS-PAGE, followed by autoradiography. This
experiment was repeated twice with similar results.
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ceptor on non-reducing, gradient SDS-PAGE gels
(Fig. 10). As others have shown, the normal prore-
ceptor (Fed) is ¢rst synthesized as a monomer, pro-
cessed to a dimer with the creation of disul¢de link-
ages, and then to a tetramer as the protein migrates
through the Golgi on its way to the plasma mem-
brane [36]. No bands were observed in the lanes from
glucose-deprived cells (Starved). Concerned that the
non-reducing elution conditions did not allow the
release of the alternative proreceptor from the anti-
body-linked Sepharose beads, we analyzed the relea-
sate and found similar radioactivity (25 500 cpm for
fed cells and 24 350 cpm for starved cells). In addi-
tion, eluted material which was subsequently reduced
with LME and applied to an SDS-PAGE gel resulted
in the expected migration of the alternative prorecep-
tor (data not shown). Together this infers that the
alternative proreceptor aggregates in high molecular
weight complexes under non-reducing conditions.
This occurs despite the presence of SDS. Note once
again the consistent presence of GRP78 in the
starved conditions which is released from the alter-
native proreceptor during elution.
3.6. Functional consequence of glucose deprivation
IR tyrosine kinase activity is imperative for insulin
signaling. To examine if glucose deprivation alters
the ability of the proreceptor to undergo insulin-
stimulated autophosphorylation, we analyzed the in
vitro phosphorylation of the proreceptor from fed,
glucose-deprived, and refed cells (Fig. 11). Consistent
with the ¢ndings of others [17], the normal prorecep-
tor exhibits insulin-sensitive autophosphorylation
(Veight-fold stimulation). In contrast, the alterna-
tive proreceptor showed no insulin sensitive auto-
phosphorylation although there was an equivalent
amount of basal activity. The intermediate prorecep-
tor showed elevated basal phosphorylation and re-
duced insulin sensitivity (Vtwo-fold). The mature
L-subunit2 shows similar insulin-stimulated auto-
phosphorylation among the three treatment para-
digms indicating that glucose deprivation does not
alter the function of the mature receptor.
4. Discussion
In the present report, we have extended our earlier
studies which demonstrated that glucose deprivation
alters the glycosylation and processing of the IR [6].
Speci¢cally we show that the alternative proreceptor
form does not oligomerize as does the normal pro-
receptor, exhibit insulin-sensitive autophosphoryla-
tion, or undergo processing and maturation. Rather
the alternative proreceptor, and the intermediate
form, appear to be targeted to the proteasome for
degradation based on sensitivity to proteasome in-
hibitors. Interestingly, the accumulated degradation
Fig. 11. Insulin-stimulated autophosphorylation in vitro. Cells
were maintained in medium with or without glucose for 24 h.
To one set, glucose was added back for 1 h. IR was immuno-
precipitated from total membranes (V3.5 mg). Autophosphory-
lation assays using [Q-32P]ATP were performed in the absence
or presence of 1 WM insulin directly on the immune complex.
Immunoprecipitates were resolved by reducing SDS-PAGE fol-
lowed by autoradiography. This experiment was repeated four
times with similar results.
Fig. 10. Oligomerization of normal and alternative forms of the
proreceptor. Fed or glucose-deprived cells were pulsed with
[35S]methionine/cysteine for 30 min. Cells were then chased in
the presence or absence of glucose, as appropriate, for the times
indicated. At each time point, total membranes were collected.
After extraction, receptor was immunoprecipitated with anti-L-
subunit antibody. Receptor was eluted from immune complexes
with Laemmli sample dilution bu¡er in the absence of reducing
reagent. The sample was separated on a 3^10% gradient gel.
The dried gel was exposed to ¢lm for 5 days. This experiment
was repeated with identical results.
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products migrate on an SDS-PAGE gel similarly to
that of the in vitro products of SPC1 digestion. This
may be fortuitous or may indicate that the aberrant
proreceptors escape degradation, in the presence of
proteasome inhibitors, by erroneous tra⁄cking to the
Golgi which contains SPC1, putatively responsible
for the normal cleavage of native proreceptor.
We also show that the aberrant proreceptor forms
interact with GRP78 in the ER which may in part
cause their sequestration and targeted degradation.
While ours is the ¢rst study to examine the interac-
tion between GRP78 and the insulin proreceptor in
adipocytes, a role for GRP78 in the processing of the
IR has been predicted based on studies in overex-
pression studies using receptors with amino acid sub-
stitutions. Alterations at selected glycosylation sites
leads to impaired processing as mentioned earlier [9^
12]. In addition, naturally occurring mutations a¡ect
receptor transport [37^40]. Accili et al. have recon-
structed three of these mutants (N15K, H209R, and
F382V) in vitro and overexpressed them in NIH 3T3
¢broblasts [15]. Of these the Arg209 and Val382 mu-
tants were found in a complex with GRP78. The
Lys15 mutant did not co-precipitate with GRP78,
despite its retention in the ER.
Two other groups have examined the e¡ect of glu-
cose deprivation on IR expression. In human IM9
lymphocytes, Briata et al. showed that insulin bind-
ing was reduced by 70% after 1 month of glucose
deprivation [41]. This of course di¡ers signi¢cantly
from our protocol with only 24 h of deprivation.
In our studies, the level of mature IR in the plasma
membrane of 3T3-L1 adipocytes was reduced by
only 12% [6,29]. Interestingly, Briata et al. indicated
that the morphology and growth rate of the glucose-
deprived IM9 cells was the same as those cells main-
tained in 25 mM glucose. The same was true for
HepG2 cells in their studies. Podskalny et al. showed
that glucose-deprived CHO cells showed an increase
in IR a⁄nity, with little change in receptor number
[42]. While the reason for the change in a⁄nity was
not apparent in CHO cells, the similarity in receptor
number between fed and glucose-deprived cells is
consistent with our own studies as mentioned above.
Kornfeld’s group in the early 1980s [43] showed
that glucose deprivation of CHO cells leads to the
synthesis of immature dolichol-linked oligosaccha-
rides. They called this synthetic path the ‘alternative’
path for oligosaccharide biosynthesis. Structural
analysis of the oligosaccharide revealed a predomi-
nance of Man5GlcNAc2 which was resistant to endo-
glycosidase H (endoH) digestion. This contrasts to
the normal core oligosaccharide which has the struc-
ture of Man9GlcNAc2 (after glucose trimming) and
is sensitive to endoH. The alternative structure was
also revealed in mutant cells (Class E thy-1 lympho-
mas) which lack K-1,3 mannosyltransferase, the en-
zyme responsible for transferring mannose from
GDP to dolichol [44]. While in the thy-1 cells GDP
mannose accumulates, in glucose-deprived cells the
GDP mannose pool is depleted. The result is the
same however, i.e., the terminal four mannose resi-
dues normally provided from dolichol (through the
GDP mannose pool) are missing in the alternative
structure [45]. While we have not proven the struc-
ture of the oligosaccharide generated in glucose-de-
prived 3T3-L1 cells, lack of sensitivity of the alter-
native proreceptor to endoH treatment [6] is
consistent with Kornfeld’s identi¢cation. Interest-
ingly, acid hydrolase in thy-1 cells is targeted appro-
priately to the lysosomal compartment but is func-
tionally compromised [46]. On the other hand, about
50% of the proteins are not processed at all [47].
While not examined in these studies, we would pre-
dict that the insulin proreceptor is among the unpro-
cessed proteins.
Over the past decade, evidence has accumulated
that implicates protein misfolding in the ER in a
growing number of human diseases as a result of
genetic mutations in the primary sequence or alter-
ations in post-translational modi¢cations [48,49].
Glucose deprivation in some ways mimics the genetic
de¢ciency of phosphomannomutase seen in Carbo-
hydrate-de¢cient Glycoprotein Syndrome (CDGS)
type1a. These patients have a point mutation in
phosphomannomutase 2 (PMM2) [50] which leads
to protein underglycosylation and oligosaccharide
truncation [51,52]. In both the glucose-deprived and
PMM2-de¢cient state, cellular levels of GDP man-
nose are reduced which causes the aberrant protein
glycosylation. The ER in CDGS ¢broblasts appears
dilated and the cytoplasm contains granular occlu-
sions [53] both signs of premature aging. We are
currently assessing IR expression and function in ¢-
broblasts from CDGS type1a patients for compari-
son with glucose-deprived adipocytes.
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